Survival · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Antibiotic resistance: change from baseline in P aeruginosa CFU/g of sputum at week 24 · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Adverse events: any adverse event in the comparative phase · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in adverse events: any adverse event in the comparative phase compared with continuous cycles alternating placebo with tobramycin (low certainty).
1 finding from 1 review
Antibiotic resistance: frequency of tobramycin‐resistant P aeruginosa · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: anti‐pseudomonal antibiotics showed no clear difference in antibiotic resistance: frequency of tobramycin‐resistant P aeruginosa compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Change in height · children with X‐linked hypophosphataemia
Summary of findings ‐ recombinant growth hormone showed no clear difference in longitudinal growth: change in height SDS compared with placebo or no intervention (low certainty).
1 finding from 1 review
Measures of mineral metabolism: change in serum phosphate mmol/L · children with X‐linked hypophosphataemia
It is very uncertain whether summary of findings ‐ recombinant growth hormone changes measures of mineral metabolism: change in serum phosphate mmol/L compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Alkaline phosphatase · children with X‐linked hypophosphataemia
1 finding from 1 review
Measures of renal function: change in TmP/GFR · children with X‐linked hypophosphataemia
It is very uncertain whether summary of findings ‐ recombinant growth hormone changes measures of renal function: change in TmP/GFR compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Body proportions: sitting height SDS · children with X‐linked hypophosphataemia
Summary of findings ‐ recombinant growth hormone showed no clear difference in body proportions: sitting height SDS compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Adverse effects · children with X‐linked hypophosphataemia
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · children and young adults with CF
1 finding from 1 review
Height velocity (cm/year) · children and young adults with CF
1 finding from 1 review
Change in weight (kg) · children and young adults with CF
1 finding from 1 review
QoL · children and young adults with CF
1 finding from 1 review
Fasting blood glucose (mg/dL) · children and young adults with CF
1 finding from 1 review
Number of pulmonary exacerbations or hospitalisations · children and young adults with CF
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · children and young adults with CF
1 finding from 1 review